Navigation Links
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
Date:12/1/2008

MSI-1436 and two subjects in each dosing group will receive placebo. The multiple ascending dose protocol has an adaptive design permitting the enrollment of additional subjects in each cohort. Data from the study is expected in the first half of 2009.

MSI-1436 is also being evaluated in preclinical studies using a once-weekly subcutaneously administered formulation which Genaera expects to utilize in Phase 2 clinical trials in the second half of 2009.

About Trodusquemine (MSI-1436)

Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in Phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in Phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations a
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)...  Cyberonics, Inc. (NASDAQ: CYBX ) today announced ... Quarterly highlights 1   Operating results for ... quarter of fiscal 2014, and other achievements, include: , ... 6.8%; , Strong international net sales of $13.2 million, ... , U.S. net product sales reached a new high of ...
(Date:8/21/2014)... 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), ... regenerative medicine, announced today the appointments of Andrew ("Andy") ... expanded Board of Directors. With these additions, the Asterias ... whom are independent. Andy Arno , ... growth companies. He is currently Managing Director of Emerging ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... 9, 2011 UCL Business (UCLB), a wholly owned ... Dickinson and Company), a leading global medical technology company, ... detection of ovarian and breast cancers to ultimately enable ... demonstrates how UCL and the Institute for Women,s Health ...
... Feb. 9, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... an investor briefing on Sunday, February 13 from 9 ... briefing, principal investigators from the VEGF Trap-Eye clinical studies ... Angiogenesis, Exudation and Degeneration 2011 meeting being held in ...
Cached Medicine Technology:BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 2BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 3BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 4Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 2Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 3Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 4Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 5
(Date:8/21/2014)... 21, 2014 According to a new ... Device System Market- Global Industry Analysis, Size, Share, Growth, ... device market was valued at USD 1,531.2 million in ... of 22.8% from 2013 to 2019, to reach an ... Globally, the microfluidic device market is witnessing significant growth ...
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... the Medical Cannabis Network that a company located in ... to be the only marijuana patient verification ... like to welcome this new entity to our growing ... due to our belief that these claims are inaccurate. ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Researchers report that ... cellular connections -- in their brains compared with typical ... possible to reduce the number of extra synapses through ... brain where brain cells (neurons) connect and communicate with ... impact on how the brain functions, theorized neuroscientists at ...
(Date:8/21/2014)... United Benefit Advisors (UBA), the nation’s ... to announce Trinity Benefit Advisors as its newest ... Benefit Advisors is a full service firm that ... Their consultative approach is comprised of four components: ... monitoring. Their dedication to effective results and absolute ...
(Date:8/21/2014)... 2014 The report "Indoor ... Hybrid), Maps and Navigation, Location based analytics, ... - Worldwide Market Forecasts and Analysis (2014 ... location market into various sub-segments with an ... report also identifies the factors driving this ...
Breaking Medicine News(10 mins):Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:Kids With Autism Have Extra Brain Connections, Study Says 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 4
... Do adolescents get enough exercise and eat the right ... Researchers analyzed the behavior of almost 900 11-to-15 year-olds ... and dietary risk behaviors, almost half had at least ... of the health guidelines in the study. ...
... the protein EGFR are important for the development of lung ... However, not all individuals// express the same mutant EGFR, for ... of EGFR and some have a mutation that affects the ... ,The potential of therapeutics to benefit individuals with ...
... The most recent Cochrane Review concluded antidepressants bupropion (Zyban) ... smoking and have few side-effects, but selective Serotonin reuptake ... ,Although nicotine medications are known to ... them or wants to use them. One possible alternative ...
... new report finds that less number of women aged 40 ... declining mammography rate could mean more breast cancer deaths down ... rates kept increasing during the 1990s, and scientists are disturbed ... reminded that, despite mammography being a test that's been around ...
... women who take folic acid supplements during their early pregnancy ... baby up to 40%. The Study results were published in ... ,Folic acid, a synthetic compound of a B vitamin ... neural tube disorders such as spina bifida. But its impact ...
... Scientists at UC Irvine have discovered that learning appears to ... hallmarks of Alzheimer's disease.// The finding suggests that the elderly, ... of this degenerative disease. The study appears in the Jan. ... ,This study with genetically modified mice is the first to ...
Cached Medicine News:Health News:Assessing Diet and Exercise Behaviors in Adolescents 2Health News:Mammography Saves Life-Beware Women Over 40 2Health News:Folic Acid Reduces Risk Of Cleft Lip 2Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2
... and best value in high performance electronic ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
... an Entire Column of a 384 Well Plate ... with 384 well plates, you need a pipettor ... Thats exactly what you get with our 16-channel ... (see Impact/Impact2), this innovation was specifically designed to ...
... a 384 Well Plate at Once , To ... you need a pipettor that can adapt to ... get with our 16-channel Impact pipettor., Available with ... was specifically designed to allow you to transfer ...
Medicine Products: